###### Key questions

What is already known about this subject?
=========================================

-   Several studies have reported neutrophil to lymphocyte ratio (NLR) as an unfavourable prognostic indicator for patients with gastrointestinal, lung, renal and gynaecological cancers.

-   In the breast cancer setting, the results of published trials evaluating the relationship between NLR and outcome are controversial.

-   Evidence of a prognostic role for NLR has been obtained mainly from studies on women of Asian race, whereas only three papers have included patients of Europe race.

What does this study add?
=========================

-   To the best of our knowledge, this is the first study to show a significant correlation between high NLR and worse prognosis in early breast cancer Caucasian patients by means of propensity score-matched analysis.

-   We analysed the prognostic significance of NLR in a highly selected population of patients with breast cancer, specifically, stage I and IIA breast cancer.

-   The propensity procedure was chosen by virtue of its ability to yield robust and scientifically sound results.

How might this impact on clinical practice?
===========================================

-   Our study suggests that presurgery NLR is strongly associated with distant metastasis-free survival in a series of 300 Italian patients with early breast cancer. Prospective studies are needed to validate the introduction of NLR assessment in everyday clinical practice for prediction of cancer recurrence in order to guide decision-making for adjuvant therapy.

Introduction {#s1}
============

Breast cancer is a commonly diagnosed malignancy and the leading cause of cancer death in women worldwide.[@R1] Despite the widespread adoption of adjuvant treatments having resulted in improved survival, nearly 20% of patients with breast cancer still suffer from recurrence of disease.[@R2]

The validated clinical and molecular prognostic factors used in treatment decision-making for breast cancer include tumour stage, age, endocrine receptor status, Her-2 status, Ki67 value, number of involved regional lymph nodes, tumour histology, grade and presence of vascular invasion; additional biomarkers, namely, tumour infiltrating lymphocytes, urokinase plasminogen activator inhibitors and multigene signatures, have recently been investigated, but few of these met the requirements for ideal markers to justify their routine clinical use.[@R5]

Increasing evidence suggests that cancer-related inflammatory response plays a role in the development and progression of several malignancies. For instance, impairment of adaptive immune responses during chronic inflammation may favour promotion of tumour growth, angiogenesis and cancer cell survival.[@R6]

Changes in blood parameters reflecting systemic inflammation, such as C reactive protein, proinflammatory cytokines, white cell counts and platelet-to-lymphocyte ratio, have been linked to poor outcome in patients with cancer.[@R11] [@R12] In this regard, cell-mediated immunity may be reflected by lymphocyte count, whereas systemic inflammation may be suggested by neutrophilia. Consequently, neutrophil to lymphocyte ratio (NLR), calculated as the neutrophil count divided by the lymphocyte count, may represent an easily measurable and inexpensive marker of systemic inflammation. Several studies and two meta-analyses consistently reported NLR as an unfavourable prognostic indicator for patients with gastrointestinal, lung, renal and gynaecological cancers.[@R13]

In the breast cancer setting, the results of published trials evaluating the relationship between NLR and outcome are controversial, and a recent meta-analysis including eight trials published between 2012 and 2014 has shown that elevated NLR is strongly associated with poor survival. Of note, the available data mainly concern women of Asian race.[@R22]

The purpose of our study was to clarify the correlation between presurgery NLR and distant metastasis-free survival **(**DMFS) in a series of 300 Caucasian patients with early breast cancer. The propensity score-matched analysis was chosen for statistical evaluation to avoid risk of confounding bias.[@R25]

Patients and methods {#s2}
====================

A total of 300 female patients with histologically proven early (T1--2, N0--1, non-metastatic) breast cancer treated at our Institution from July 1999 to June 2015 were considered for this retrospective study. Three hundred and twenty-seven patients, whose clinical records were lacking data relevant to this study or because of preoperative chemotherapy, and 24 patients with abnormal white cell counts possibly due to concomitant infectious diseases, autoimmune diseases, or other recognisable inflammatory conditions, thus possibly causing misinterpretation of results, were primarily excluded. The following data were collected: age, menopausal status, histological tumour type, tumour size, tumour-node-metastasis stage, degree of histological differentiation, expression of oestrogen and/or progesterone receptor, HER2 status, Ki67 levels, recurrence rate and DMFS rates. Patient and tumour characteristics of the series are summarised in [table 1](#ESMOOPEN2016000038TB1){ref-type="table"}. HER2 status was defined using the HercepTest, integrated by a FISH confirmatory test in all cases of 2+ level of staining.

###### 

Characteristics of the series (300 patients)

                          Number (%)
  ----------------------- ------------
  Age (years)             
   ≤35                    9 (3)
   \>35                   291 (97)
  Menopausal status       
   Premenopausal          139 (46.3)
   Postmenopausal         161 (53.7)
  Histological type       
   Ductal                 270 (90)
   Lobular                20 (6.7)
   Others                 10 (3.3)
  Tumour size             
   T1                     190 (63.3)
   T2                     110 (36.7)
  Nodal status            
   N0                     192 (64)
   N1                     108 (36)
  Grading                 
   Low                    34 (11.3)
   Intermediate           172 (57.3)
   High                   94 (31.3)
  Oestrogen receptor      
   Positive               250 (83.3)
   Negative               50 (16.7)
  Progesterone receptor   
   Positive               235 (78.3)
   Negative               65 (21.7)
  HER2 status             
   Negative               228 (76)
   Positive               72 (24)
  Molecular subtype       
   Luminal A              77 (25.7)
   Luminal B HER2--       124 (41.3)
   Luminal B Her2+        51 (17)
   HER2-enriched          21 (7)
   Basal-like             27 (9)
  Ki-67                   
   ≤20                    102 (34)
   \> 20                  198 (66)
  NLR                     
   Low (≤1.97)            134 (44.7)
   High (\> 1.97)         166 (55.3)

NLR, neutrophil to lymphocyte ratio.

Preoperative blood cell counts were obtained within 1 week of planned surgery. In 59 (19.6%) patients, a modified radical mastectomy was performed, whereas the remaining 241 patients received breast-conservative surgery, followed by standard radiation therapy. One hundred and fifty-eight patients (52.7%) were treated with adjuvant chemotherapy plus hormonal therapy; chemotherapy or hormonal therapy alone were administered in 55 (18.3%) and 87 (29.0%) patients, respectively, according to ESMO guidelines. Patients were followed-up according to our standardised protocol, which includes a three-monthly clinical assessment for the first 2 years, with subsequent bi-annual radiological surveillance; in case of suspicion for recurrence, further diagnostic methods, always complemented by routine histopathological examination of a biopsy specimen, are carried out as appropriate.

No patient was lost to follow-up and the study was completed by 31 December 2015. The study was approved by the Institutional Review Board at the Department of Clinical and Experimental Medicine of the Second University of Naples.

Statistical analysis {#s3}
====================

Since the primary end point of the study was to individuate factors related to tumour relapse, the DMFS rate, defined as the time from breast cancer diagnosis to the date of evidence of tumour relapse, constituted the study primary end point. Patients who died of causes other than breast cancer---without experiencing tumour recurrence---were regarded as censored events at the date of death when computing the DMFS rate. Secondary end points included the identification of the best cut-off value for NLR and possible correlations between NLR and other clinicopathological characteristics. The NLR was calculated before surgery using values derived from standard laboratory blood test results.

Statistical analysis was carried out using the SPSS statistical package (SPSS Inc, Chicago, Illinois, USA) and integrated using Medcalc software V.9.4.2.0 (Mariakerke, Belgium). In all analyses, the significance level was specified as p\<0.05. Continuous data were expressed as mean±SD, range and median value. Multiple regression was performed to analyse correlations between NLR and the following prognostic variables: age, menopausal status, histology, tumour size, nodal involvement, grade of differentiation, hormonal receptor expression, HER2 status, Ki67 level and triple negativity. Receiver operating characteristic (ROC) curve analysis was used to investigate whether NLR could distinguish between recurrent and non-recurrent patients (area under the ROC curve, area under curve (AUC)). The NLR value with the best accuracy (the highest sensitivity and specificity) was selected as the NLR cut-off value. Univariate statistical analysis was determined by log-rank test (Mantel-Cox); curves were plotted using the Kaplan-Meier method, and p values and HRs with 95% CI were obtained. The independent significance of each factor was determined by the Cox proportional hazards model, following inclusion of prognostic variables showing a significant p value on univariate analysis. Moreover, Cox models were used to identify possible interactions in treatment effect between subgroups, with and without adjustment for prognostic factors. Subgroups were defined by factors showing significant value on univariate analysis or directly correlated with NLR values, namely, menopausal status, tumour size and nodal and HER2 status. All available variables (ie, age, menopausal status, histology, tumour size, nodal involvement, grade of differentiation, hormonal receptor expression, HER2 status, Ki67 level, triple negativity) were introduced in a multivariate logistic regression to calculate a propensity score for each patient. Finally, a propensity score-matched analysis, using the 1:1 nearest neighbour technique with a small caliper of 0.15 to ensure better balance, was performed to re-evaluate univariate and multivariate analyses in the matched couples.[@R25] [@R26]

Results {#s4}
=======

NLR ranged from 0.21 to 30.00 (mean 2.67±2.52, median 2.09) in the whole population (300 patients). A significant NLR increase was observed only with T2 stage (r=0.11; p=0.043). On the contrary, NLR values did not correlate with all other prognostic variables. NLR had the ability to distinguish between relapsing and non-relapsing patients, as established by ROC curve analysis (AUC=0.625, p=0.0160), which selected the value of 1.97 as that with the highest sensitivity and specificity ([figure 1](#ESMOOPEN2016000038F1){ref-type="fig"}). Consequently, 134 and 166 patients were grouped as low and high NLR, respectively. At the end of the study, 37 (12%) patients experienced distant metastases. Less than 10% of patients had a follow-up time shorter than 1 year; the DMFS rates for 1, 3, 6, 9, 12 and 15  years were 99.7%, 96.3%, 87.5%, 74.5%, 72.5% and 64.5%, respectively, having a statistically significant correlation with menopausal status, tumour size, nodal and HER2 status and elevated NLR values ([table 2](#ESMOOPEN2016000038TB2){ref-type="table"}). The DMFS rates for 1, 3, 6, 9, 12 and 15 years were, respectively, 100%, 98.9%, 91.7%, 82.7%, 82.7% and 82.7% in low NLR patients, and 99.4%, 94.3%, 84.5%, 69.2%, 66.0% and 51.4% in high NLR patients, with a statistically significant association ([figure 2](#ESMOOPEN2016000038F2){ref-type="fig"}).

###### 

Univariate analysis related to distant metastasis-free survival in 300 early stage patients with breast cancer

                          Patients, (n)   Recurrence   7-year DFS %\*   HR for Recurrence   95% CI \*HR    p Value
  ----------------------- --------------- ------------ ---------------- ------------------- -------------- ------------
  Age (≤35/\>35 years)    9/291           0/37         100/84           0.00                0.03 to 4.14   0.4123
  Pre/post Menopausal     139/161         24/13        78/91            0.46                0.23 to 0.88   **0.0194**
  Histological type                                                                                        
   Ductal                 270             30           85               //                  //             0.4852
   Lobular                20              7            77                                                  
   Others                 10              0            100                                                 
  Tumour size                                                                                              
   T1                     190             17           90               0.54                0.26 to 1.02   **0.0577**
   T2                     110             20           76                                                  
  Nodal status                                                                                             
   N0                     192             15           90               0.41                0.19 to 0.75   **0.0054**
   N1                     108             22           76                                                  
  Grading                                                                                                  
   Low                    34              2            100                                                 
   Intermediate           172             21           86               //                  //             0.0812
   High                   94              14           74                                                  
  Oestrogen receptor                                                                                       
   Positive               250             30           86               1.20                0.50 to 2.93   0.6561
   Negative               50              7            78                                                  
  Progesterone receptor                                                                                    
   Positive               235             28           85               1.17                0.53 to 2.59   0.6785
   Negative               65              9            81                                                  
  HER2 status                                                                                              
   Negative               228             22           89                                                  
   Positive               72              15           76               0.56                0.23 to 1.06   **0.0711**
  Triple negativity                                                                                        
   Yes                    30              3            85               0.67                0.25 to 1.95   0.5056
   No                     270             34           85                                                  
  Ki-67                                                                                                    
   ≤20                    102             18           90               1.01                0.52 to 1.97   0.9587
   \> 20                  198             19           82                                                  
  NLR                                                                                                      
   Low (≤1.97)            134             9            89               0.45                0.25 to 0.94   **0.0337**
   High (\> 1.97)         166             28           81                                                  

p Values highlighted in bold are statistically significant.

\*Median follow-up time.

NLR, neutrophil to lymphocyte ratio.

![ROC analysis based on NLR for DMFS. In this model, sensitivity was 75.7% and specificity was 47.9%; AUC was 0.625 (95% CI 0.56 to 0.6), p=0.0160. AUC, area under curve; DMFS, distant metastasis-free survival; NLR, neutrophil to lymphocyte ratio; ROC, receiver operating characteristics.](esmoopen2016000038f01){#ESMOOPEN2016000038F1}

![DMFS of 300 early patients with breast cancer based on NLR value. DMFS, distant metastasis-free survival; NLR, neutrophil to lymphocyte ratio.](esmoopen2016000038f02){#ESMOOPEN2016000038F2}

On multivariate analysis, premenopausal status, N1 stage and a high NLR value were shown to be independent prognostic factors related to poor recurrence rate ([table 3](#ESMOOPEN2016000038TB3){ref-type="table"}).

###### 

Cox proportional hazards model related to distant metastasis-free survival in 300 early stage patients with breast cancer

                           Cox proportional hazards model                                
  ------------------------ -------------------------------- -------- ------ ------------ ------------
  Premenopausal            1.0252                           0.3645   2.78   1.36/5.67    **0.0049**
  Tumour size (T2)         0.3609                           0.3448   1.43   0.73/2.81    0.2953
  Nodal status (N1)        0.8408                           0.3515   2.31   1.16/4.60    **0.0167**
  HER2 status (positive)   0.3795                           0.3543   1.46   0.73/2.91    0.2841
  NLR (\>1.97)             0.9718                           0.3928   2.64   1.22/5.638   **0.0133**

p Values highlighted in bold are statistically significant.

NLR, neutrophil to lymphocyte ratio.

After adjusting for interfering factors related to NLR and/or probability of tumour recurrence, low NLR patients continued to display a better outcome. Particularly, significant differences were shown in postmenopausal patients (HR=2.81, 95% CI 1.14 to 6.88, p=0.0243), node negative cancers (HR=5.31, 95% CI 1.19 to 23.70, p=0.0292) and HER2-positive tumours (HR=4.78, 95% CI 1.01 to 22.62, p=0.0492) ([figure 3](#ESMOOPEN2016000038F3){ref-type="fig"}).

![Forest plot showing adjusted HRs (oblongs) and 95% CIs (bars) for distant metastasis-free survival rate in 300 early patients with breast cancer undergoing potentially curative surgery, according to subgroup effects. Univariate HRs, as well as HRs adjusted for baseline covariates and related p values, are listed on the right side. Subgroups were defined by factors showing significant correlation with NLR and recurrence rate. NLR, neutrophil to lymphocyte ratio.](esmoopen2016000038f03){#ESMOOPEN2016000038F3}

Propensity score-matched analysis {#s4a}
---------------------------------

To further corroborate the results observed in the whole series, a propensity score-matched analysis was performed. One hundred and thirteen couples were matched, except 21 and 53 patients in the low and high NLR group, respectively. The overall χ^2^ balance test was not significant (p=1.0000), and the λ1 measure was larger in the unmatched (0.540) than in the matched sample (0.478), indicating improved overall balance with matching.[@R26] In addition, before matching, the propensity score was 0.53±0.09 and 0.56±0.08, in the low and high NLR group (p=0.002), respectively. After matching, the difference between the two groups was not significant (0.55±0.08 and 0.55±0.09, respectively, p=1.000).

On univariate analysis, premenopausal status, and T2 and N1 stages as well, were confirmed to be negatively correlated with recurrence rate. Conversely, a low NLR was still significantly associated with longer disease-free survival (HR=0.40, 95% CI 0.20 to 0.89, p=0.0235 ([table 4](#ESMOOPEN2016000038TB4){ref-type="table"})). The multivariate analysis according to the Cox model excluded tumour stage, while confirming premenopausal status, N1 stage and high NLR values, as independent prognostic variables of poor outcome ([table 5](#ESMOOPEN2016000038TB5){ref-type="table"}).

###### 

Univariate analysis related to distant metastases-free survival in propensity score-matched 226 early stage breast cancers

                          Patients, (n)   Recurrence     7-year DFS %\*   HR for Recurrence   95% CI HR      p Value
  ----------------------- --------------- -------------- ---------------- ------------------- -------------- ------------
  Age (≤35/\>35 years)    9/217           0/28           100/84           0.0000              0.03 to 3.85   0.3961
  Pre/post menopausal     121/105         21/7           77/92            0.32                0.16 to 0.73   **0.0058**
  Histological type       −               −              0.5773                                              
   Ductal                 205             235            85                                                  
   Lobular                15              5              77                                                  
   Others                 6               0              100                                                 
  Tumour size             0.48            0.21 to 1.00   **0.0512**                                          
   T1                     145             13             89                                                  
   T2                     81              15             76                                                  
  Nodal status            0.32            0.13 to 0.64   **0.0023**                                          
   N0                     148             11             92                                                  
   N1                     78              17             70                                                  
  Grading                 −               −              0.1151                                              
   Low                    28              2              100                                                 
   Intermediate           130             15             86                                                  
   High                   68              11             72                                                  
  Oestrogen receptor      1.44            0.54 to 4.17   0.4240                                              
   Positive               187             22             86                                                  
   Negative               39              6              74                                                  
  Progesterone receptor   1.40            0.59 to 3.54   0.4121                                              
   Positive               177             20             86                                                  
   Negative               49              8              78                                                  
  HER2 status             0.61            0.24 to 1.37   0.2151                                              
   Negative               174             18             87                                                  
   Positive               52              10             76                                                  
  Triple negativity       1.01            0.30 to 3.41   0.9750                                              
   Yes                    22              3              78                                                  
   No                     204             25             85                                                  
  Ki-67                   1.01            0.47 to 2.14   0.9798                                              
   ≤20                    73              13             88                                                  
   \>20                   153             15             82                                                  
  NLR                     0.40            0.20 to 0.89   **0.0235**                                          
   Low (≤1.97)            113             8              88                                                  
   High (\> 1.97)         113             20             81                                                  

p Values highlighted in bold are statistically significant.

\*Median follow-up time.

NLR, neutrophil to lymphocyte ratio.

###### 

Cox proportional hazards model related to distant metastasis-free survival in propensity score-matched early stage patients with breast cancer (number 226)

  Cox proportional hazards model                                           
  -------------------------------- -------- -------- ------ -------------- --------
  Premenopausal                    1.0816   0.4387   2.94   1.25 to 6.93   0.0136
  Tumour size (T2)                 0.2619   0.4013   1.29   0.59 to 2.84   0.5141
  Nodal status (N1)                1.0217   0.4054   2.77   1.25 to 6.12   0.0117
  NLR (\>1.97)                     0.9274   0.4197   2.52   1.11 to 5.73   0.0271

NLR, neutrophil to lymphocyte ratio.

Discussion {#s5}
==========

To the best of our knowledge, this is the first study to show a significant correlation between high NLR and worse prognosis in Caucasian patients with early breast cancer by means of propensity score-matched analysis.

Despite looking apparently simple, the relationship between NLR and outcome in patients with cancer is probably a complex and multifactorial process, still poorly understood. In simple terms, a high NLR may reflect the key role of systemic inflammation in enhancing angiogenesis, tumour growth and development of metastasis.[@R27] Cancer-associated neutrophilia has been shown to promote remodelling of the extracellular matrix, which, in turn, leads to release of basic fibroblast growth factor, migration of endothelial cells and dissociation of tumour cells; additionally, neutrophil-derived reactive oxygen species are known to inhibit the cytotoxic activity of lymphocytes, to reduce the adhesion-promoting properties of the extracellular matrix, to suppress apoptosis of cancer cells and to prolong neutrophil life itself in the tumour microenvironment.[@R28] When coupled with lymphopaenia, which seems also to correlate with poor prognosis in patients with cancer, the predictive effect on cancer prognosis may be enhanced. Indeed, the role of lymphocytes in cancer control is exemplified by the strong association between high densities of tumour-infiltrating lymphocytes and better responses to both, cytotoxic treatments and outcome in patients with breast cancer.[@R31] Thus, NLR may quickly combine the prognostic strength of the above two indicators.

Actually, a high NLR has been unequivocally associated with adverse prognosis in many cancers; with regard to breast cancer, evidence of a prognostic role for NLR has been obtained mainly from studies on women of Asian race,[@R22] [@R36] whereas only three papers have included patients of Europe race. Besides, the survival of Asian patients with breast cancer is known to be longer than that of Caucasian women, probably owing more to lifestyle habits than to genetic susceptibility; however, this matter needs to be clarified by further studies.[@R37]

Another issue concerns the best approach to define the optimal cut-off value for LNR, as median, quartiles and ROC curve analysis have been variably used by different authors.

While the use of means, medians and quartiles allows division of a group or a continuous variable into two or more groups according to a purely mathematical procedure, ROC curve analysis is built by probing individual values to the final result (in this case, the presence or absence of recurrence). The result of ROC analysis, that is, the cut-off value, is the figure that proves to possess the best sensitivity and specificity in predicting the result (ie, the best prediction). For these reasons, ROC analysis, in our opinion, is the most appropriate approach.

With regard to published evidence concerning non-Asiatic patients with breast cancer, women in the highest NLR quartile (\>3.3) had a significantly shorter survival in a series of 316 cases referred to Staten Island University Hospital of NY.[@R44] In a recently published Italian trial, in which the significance of NLR was explored in 90 triple negative patients with breast cancer by means of ROC analysis, NLR \>3 was associated with worse survival.[@R45] Finally, in two cohorts of 363 and 147 patients, respectively, treated with conservative breast surgery (and intraoperative non-steroidal anti-inflammatory drugs) at Louvain University, disease-free survival and overall survival were shown to be significantly correlated with high NLR (\>3.3), as calculated by ROC analysis.[@R46]

It should be noted that the NLR cut-off value selected by ROC curve analysis in our study (1.97) is lower than that used in the abovementioned papers. An explanation for this difference may be represented by the fact that our patients had a limited stage of disease. However, to further confirm the predictive value of NLR, we carried out an additional analysis using a cut-off equal to 3, and NLR again turned out to be a strong predictor of recurrence; in fact, the 7-year DMFS in 220 low and 80 high NLR breast patients with cancer was 87.3% and 77.1%, respectively (HR=0.53; 95% CI 00.23 to 1.02; p=0.0587).

Interestingly, in the whole population (300 patients) and in the 226 score-matched patients, the only variables showing prognostic significance were premenopausal status, N1stage and high NLR; in the subgroup analysis (Cox model), the prognostic value of NLR in node negative patients (HR=5.31, p=0.0292) emerged as the most intriguing finding. Indeed, in clinical practice, the latter patients are not always treated with postoperative chemotherapy, thus raising the issue as to whether early oestrogen-receptor positive patients with breast cancer should be more aggressively managed.

In conclusion, we have, for the first time, analysed the prognostic significance of NLR in a highly selected population of patients with breast cancer, specifically, stage I and IIA breast cancer, by means of propensity score analysis. This statistical procedure was chosen by virtue of its ability to yield robust and scientifically sound results. One limitation of our work lies in the retrospective nature of the study; thus, prospective studies are needed to validate its accuracy prior to introducing NLR assessment in every-day clinical practice for prediction of cancer recurrence.
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